WebJul 13, 2024 · Also known as ejaculatory anhedonia, sexual anhedonia means that a person can ejaculate without feeling pleasure. While it’s a condition mostly found in males, it can occur in women, as well. It’s often treated with the antidepressant bupropion which has been shown to help sexual dysfunction in patients that don’t have depression. WebSexual anhedonia in males is also known as 'ejaculatory anhedonia'. This condition means that the man will ejaculate with no accompanying sense of pleasure. [21] The condition is most frequently found in males, but females can experience lack of pleasure when the body goes through the orgasm process as well. Sexual anhedonia may be caused by:

Retigabine - Wikipedia

WebRetigabine ( INN) or ezogabine ( USAN) is an anticonvulsant used as an adjunctive treatment for partial epilepsies in treatment-experienced adult patients. [2] The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline. WebAug 17, 2024 · Case in point: anhedonia. Defined as "a psychological condition characterized by inability to experience pleasure in normally pleasurable acts," anhedonia refers to the absence of good feelings someone might expect from things and activities they once enjoyed, like friendship, food, sex or music. golowshot.com

Ezogabine, a recently discontinued epilepsy drug, robustly decreases …

WebMar 2, 2024 · Their study showed that ezogabine (also known as retigabine), a drug that opens KCNQ2/3 type of potassium channels in the brain, is associated with significant … WebEzogabine is used along with other medications to control partial onset seizures (seizures that involve only one part of the brain) in adults. Ezogabine is in a class of medications called anticonvulsants. It works by reducing abnormal electrical activity in the brain. How should this medicine be used? Ezogabine comes as a tablet to take by mouth. WebEzogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. healthcare teamwork video